Evidence map›Paper›PMID 39974282›Full record

ArticleOpen forum infectious diseases2025

A Longitudinal Description of the Health-Related Quality of Life Among Individuals at High Risk After SARS-CoV-2 Infection: A Dutch Multicenter Observational Cohort Study.

Magda Vergouwe, Emma Birnie, Sarah van Veelen, Jason J Biemond, Brent Appelman, Hessel Peters-Sengers, Godelieve J de Bree, Stephanie Popping, W Joost Wiersinga, TURN-COVID Study Group

Registry-linked trialAbstract read
In one paragraph

Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05195060 (The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2), which is not on this map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05195060 completednot on this map

The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2

TypeobservationalSponsorAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Ran2021 to 2025Enrolled1,178ConditionsCOVID-19Armscasirivimab with imdevimab, sotrovimab, molnupiravir
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Magda VergouweCenter for Infection and Molecular Medicine, Amsterdam University Medical Center, Location AMC, University of Amsterdam, Amsterdam, the Netherlands.ORCID https://orcid.org/0000-0002-3751-7578
Emma BirnieCenter for Infection and Molecular Medicine, Amsterdam University Medical Center, Location AMC, University of Amsterdam, Amsterdam, the Netherlands.ORCID https://orcid.org/0000-0001-8482-0046
Sarah van VeelenCenter for Infection and Molecular Medicine, Amsterdam University Medical Center, Location AMC, University of Amsterdam, Amsterdam, the Netherlands.ORCID https://orcid.org/0009-0001-0839-9808
Jason J BiemondCenter for Infection and Molecular Medicine, Amsterdam University Medical Center, Location AMC, University of Amsterdam, Amsterdam, the Netherlands.
Brent AppelmanCenter for Infection and Molecular Medicine, Amsterdam University Medical Center, Location AMC, University of Amsterdam, Amsterdam, the Netherlands.ORCID https://orcid.org/0000-0002-4560-8410
Hessel Peters-SengersCenter for Infection and Molecular Medicine, Amsterdam University Medical Center, Location AMC, University of Amsterdam, Amsterdam, the Netherlands.ORCID https://orcid.org/0000-0003-3145-864X
Godelieve J de BreeAmsterdam institute for Immunology and Infectious Diseases, Infectious Diseases, Amsterdam, the Netherlands.
Stephanie PoppingCenter for Infection and Molecular Medicine, Amsterdam University Medical Center, Location AMC, University of Amsterdam, Amsterdam, the Netherlands.
W Joost WiersingaCenter for Infection and Molecular Medicine, Amsterdam University Medical Center, Location AMC, University of Amsterdam, Amsterdam, the Netherlands.ORCID https://orcid.org/0000-0003-2277-1343
TURN-COVID Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Health-related quality of life (HRQoL) data post-COVID-19 in patients with medical conditions associated with severe disease are lacking. Here, we assess the longitudinal impact of COVID-19 on HRQoL and employment status in individuals at high risk. Methods: This multicenter prospective cohort study included individuals at high risk for severe disease who were hospitalized or not-hospitalized with SARS-CoV-2 infection (September 2021-February 2024). Questionnaires about HRQoL and employment status were collected at 3, 6, and 12 months post-COVID-19 and retrospectively recalled and reported for pre-COVID-19. With a mixed effects model, we assessed the course of and risk factors for changes in HRQoL utility score. Results: Among 332 individuals (median age, 59.8 years [IQR, 48.8-67.1]; 50.6% female), 184 (55.4%) were hospitalized for COVID-19 (intensive care unit admission, 12.0%). High-risk factors included solid organ transplantation (19.6%), hematologic malignancies (28.0%), and immunosuppressive medication use (56.6%). The median HRQoL utility score declined from 0.85 (IQR, 0.74-1.00) pre-COVID-19 to 0.81 (0.70-0.92) 12 months post-COVID-19 ( Conclusions: Solid organ transplant recipients and individuals requiring oxygen therapy experience a substantial HRQoL decline over 12 months post-COVID-19. Moreover, almost half of employed participants reported COVID-19-related sick leave, correlating with lower HRQoL. This highlights the continuous burden of COVID-19 for this vulnerable population and supports the implementation of preventive approaches.

Indexed as

COVID-19health-related quality of lifeHRQoL utility scoreimmunocompromisedSARS-CoV-2

Identifiers

PMID39974282
PMCPMC11837172

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.